Literature DB >> 11509673

Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis.

J K Chen1, J Capdevila, R C Harris.   

Abstract

The ubiquitous cytochrome P450 hemoproteins play important functional roles in the metabolism and detoxification of foreign chemicals. However, other than established roles in cholesterol catabolism and steroid hormone biosynthesis, their cellular and/or organ physiological functions remain to be fully characterized. Here we show that the cytochrome P450 epoxygenase arachidonic acid metabolite 14,15-epoxyeicosatrienoic acid (14,15-EET) inhibits apoptosis induced by serum withdrawal, H(2)O(2), etoposide, or excess free arachidonic acid (AA), as determined by DNA laddering, Hoechst staining, and fluorescein isothiocyanate-labeled annexin V binding. In the stable transfectants (BM3 cells) expressing a mutant bacterial P450 AA epoxygenase, F87V BM3, which was genetically engineered to metabolize arachidonic acid only to 14,15-EET, AA did not induce apoptosis and protected against agonist-induced apoptosis. Ceramide assays demonstrated increased AA-induced ceramide production within 1 h and elevated ceramide levels for up to 48 h, the longest time tested, in empty-vector-transfected cells (Vector cells) but not in BM3 cells. Inhibition of cytochrome P450 activity by 17-octadecynoic acid restored AA-induced ceramide production in BM3 cells. Exogenous C2-ceramide markedly increased apoptosis in quiescent Vector cells as well as BM3 cells, and apoptosis was prevented by pretreatment of Vector cells with exogenous 14,15-EET and by pretreatment of BM3 cells with AA. The ceramide synthase inhibitor fumonisin B1 did not affect AA-induced ceramide production and apoptosis; in contrast, these effects of AA were blocked by the neutral sphingomyelinase inhibitor scyphostatin. The pan-caspase inhibitor Z-VAD-fmk had no effect on AA-induced ceramide generation but abolished AA-induced apoptosis. The antiapoptotic effects of 14,15-EET were blocked by two mechanistically and structurally distinct phosphatidylinositol-3 (PI-3) kinase inhibitors, wortmannin and LY294002, but not by the specific mitogen-activated protein kinase kinase inhibitor PD98059. Immunoprecipitation followed by an in vitro kinase assay revealed activation of Akt kinase within 10 min after 14,15-EET addition, which was completely abolished by either wortmannin or LY294002 pretreatment. In summary, the present studies demonstrated that 14,15-EET inhibits apoptosis by activation of a PI-3 kinase-Akt signaling pathway. Furthermore, cytochrome P450 epoxygenase promotes cell survival both by production of 14,15-EET and by metabolism of unesterified AA, thereby preventing activation of the neutral sphingomyelinase pathway and proapoptotic ceramide formation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509673      PMCID: PMC87364          DOI: 10.1128/MCB.21.18.6322-6331.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  61 in total

1.  Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid.

Authors:  S C Hwang; D Y Jhon; Y S Bae; J H Kim; S G Rhee
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

Review 2.  Cyclooxygenase and lipoxygenase inhibitors in cancer therapy.

Authors:  G Ara; B A Teicher
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1996-01       Impact factor: 4.006

3.  The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells.

Authors:  C Bortuzzo; R Hanif; K Kashfi; L Staiano-Coico; S J Shiff; B Rigas
Journal:  Biochim Biophys Acta       Date:  1996-05-20

4.  Apoptosis and APC in colorectal tumorigenesis.

Authors:  P J Morin; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  An active site substitution, F87V, converts cytochrome P450 BM-3 into a regio- and stereoselective (14S,15R)-arachidonic acid epoxygenase.

Authors:  S Graham-Lorence; G Truan; J A Peterson; J R Falck; S Wei; C Helvig; J H Capdevila
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

6.  Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway.

Authors:  F Pica; O Franzese; C D'Onofrio; E Bonmassar; C Favalli; E Garaci
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

Review 7.  Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system.

Authors:  K Makita; J R Falck; J H Capdevila
Journal:  FASEB J       Date:  1996-11       Impact factor: 5.191

8.  Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis.

Authors:  D G Tang; Y Q Chen; K V Honn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  Effect of n-3 and n-6 fatty acids on proliferation and differentiation of promyelocytic leukemic HL-60 cells.

Authors:  H S Finstad; S O Kolset; J A Holme; R Wiger; A K Farrants; R Blomhoff; C A Drevon
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

10.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.

Authors:  W B Campbell; D Gebremedhin; P F Pratt; D R Harder
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

View more
  45 in total

1.  The ω-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation.

Authors:  Pei H Cui; Nenad Petrovic; Michael Murray
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Role of intracellular calcium and phospholipase A2 in arachidonic acid-induced toxicity in liver cells overexpressing CYP2E1.

Authors:  Andres A Caro; Arthur I Cederbaum
Journal:  Arch Biochem Biophys       Date:  2006-11-03       Impact factor: 4.013

3.  Development of a high throughput cell-based assay for soluble epoxide hydrolase using BacMam technology.

Authors:  Wensheng Xie; Xiaoyan Tang; Quinn Lu; Robert S Ames; Steven J Ratcliffe; Hu Li
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

Review 4.  TRP channel Ca(2+) sparklets: fundamental signals underlying endothelium-dependent hyperpolarization.

Authors:  Michelle N Sullivan; Scott Earley
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-11       Impact factor: 4.249

5.  The biological actions of 11,12-epoxyeicosatrienoic acid in endothelial cells are specific to the R/S-enantiomer and require the G(s) protein.

Authors:  Yindi Ding; Timo Frömel; Rüdiger Popp; John R Falck; Wolf-Hagen Schunck; Ingrid Fleming
Journal:  J Pharmacol Exp Ther       Date:  2014-04-24       Impact factor: 4.030

6.  Metformin effectively treats Tsc1 deletion-caused kidney pathology by upregulating AMPK phosphorylation.

Authors:  Yili Fang; Fang Li; Chenyang Qi; Xing Mao; Feng Wang; Zhonghua Zhao; Jian-Kang Chen; Zhigang Zhang; Huijuan Wu
Journal:  Cell Death Discov       Date:  2020-06-15

7.  Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.

Authors:  Guangzhi Chen; Renfan Xu; Yinna Wang; Peihua Wang; Gang Zhao; Xizhen Xu; Artiom Gruzdev; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-26       Impact factor: 4.310

8.  Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.

Authors:  Xiaocui Qin; Qiaoqi Wu; Lifang Lin; Aimin Sun; Shuhu Liu; Xiaowen Li; Xiong Cao; Tianming Gao; Pengcheng Luo; Xinhong Zhu; Xuemin Wang
Journal:  Mol Neurobiol       Date:  2014-08-17       Impact factor: 5.590

Review 9.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

10.  Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia.

Authors:  Nicole Y Marden; Eva Fiala-Beer; Shi-Hua Xiang; Michael Murray
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.